MarketsNotableEmergingDeveloping
5.0
Q2 2026 earnings outlook highlights commodity sector strength and domestic slowdown
InfoMoney·BR·2 days ago
MarketsSingle-sourceLow
2.1
Antibiotice reports Q2 2026 revenue decline exceeding projections
Antibiotice (ATB) reported a 10.37% year-on-year decrease in net turnover for Q2 2026, underperforming its internal target of a 7.34% decline. The company also recorded an operating margin of 10%, signaling potential operational headwinds for the state-owned pharmaceutical entity.
Score Breakdown
Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.2
Related signals
8 foundMarketsSingle-source
2.1
Euro Auto Plastic Systems reports 27.6% revenue growth and tripled profits in 2025
Ziarul FinanciarLO·RO · FR·about 22 hours ago
MarketsSingle-source
2.1
Polpharma outlines growth strategy for newly acquired Romanian pharmaceutical firm Biofarm
Ziarul FinanciarLO·PL · RO·about 23 hours ago
MarketsSingle-source
2.1
Novartis Q2 earnings exceed projections despite ongoing patent expiration headwinds
Valor Econômico·CH · US·2 days ago
MarketsSingle-source
2.1
Exclusive Networks Romania reports record revenue but 42% profit decline in 2025
Ziarul FinanciarLO·RO·2 days ago
MarketsSingle-source
2.1
Hiab reports Q2 2026 adjusted operating profit of 61 million euros
Dagens IndustriLO·FI·1 day ago
MarketsSingle-source
2.1
Novartis earnings impacted by rising interest expenses and tax burdens
Börsen-Zeitung·CH·2 days ago
MarketsSingle-source
2.1
IBM reports Q2 2026 earnings of $2.27 per share, meeting revised guidance
Dagens IndustriLO·US·about 16 hours ago